This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Real validated PRLR Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-PRLR WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~69.5 kDa | |
| Observed band | 65-95 kDa | |
| Gel | 10–12% | |
| Negative control | siRNA / KO lysate |
| PTM | Glycosylated + Cleaved | |
| Caveat | N-glycosylation increases mass | |
| Regulation | Estrogen up | |
| Isoform | 9 isoform(s) |
Literature-validated Western blot parameters for PRLR — gel percentage, transfer, blocking, antibody incubation and detection, extracted from published methods.
| Sample / lysate | human MCF-7 . After electrophoresis, proteins were transferred to a nitrocellulose membrane at 150 mA for 50-90 minutes. Blocked the membrane with 5% non-fat milk/TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-PRLR antigen affinity purified polyclonal antibody (Catalog # PB9782) at 0.5 μg/mL overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:5000 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for PRLR at approximately 65, 95 kDa. The expected band size for PRLR is at 70 kDa |
| Gel % | 10–12% |
| Load | 30 ug |
| Transfer | nitrocellulose membrane, 150 mA, 50–90 min |
| Membrane | nitrocellulose |
| Blocking | 5% non-fat milk / TBS, 1.5 h RT |
| Primary antibody | 0.5 µg/mL |
| Primary incubation | overnight at 4 °C |
| Secondary antibody | goat anti-rabbit IgG-HRP, 1:5000 |
| Wash | TBS-0.1% Tween, 3 × 5 min |
| Detection | ECL |
| Exposure / imaging | Tanon 5200 |
| Observed band | 65, 95 kDa |
PRLR has a 69.5 kDa predicted backbone but runs at 65-95 kDa on Western blot due to heavy N-glycosylation at three extracellular sites and splice-isoform diversity.
| diffuse band spanning roughly 65-95 kDa | mature PRLR monomer carrying variable N-linked glycan load on top of the 69.5 kDa unmodified backbone |
| broad or smeared band rather than one sharp line | heterogeneous glycan occupancy/processing across the three extracellular N-glycosylation sites (Asn59, Asn104, Asn233) |
| fainter band near 69-70 kDa alongside the main band | a less-glycosylated or precursor-like PRLR species closer to the predicted unmodified mass |
| multiple distinct bands at different molecular weights | reflects the 9 annotated PRLR splice isoforms, which include both membrane-bound and soluble/secreted forms |
| no doubled band at roughly twice the monomer size under reducing conditions | PRLR homodimerizes non-covalently upon prolactin binding; its annotated disulfides are intrachain, not inter-chain, so no covalent dimer survives reducing SDS-PAGE |
| Predicted mass from UniProt | the 622-aa PRLR backbone predicts a 69.5 kDa protein before any post-translational modification |
| N-glycosylation at Asn59, Asn104, Asn233 | adds variable glycan mass that shifts and broadens the apparent band up to the observed 65-95 kDa range |
| Signal peptide cleavage (residues 1-24) | removal of the signal peptide slightly reduces the mature membrane-bound protein's mass relative to the unprocessed precursor |
| Alternative splicing (9 named isoforms) | generates protein species of differing length, including membrane-bound and soluble/secreted forms, seen as additional bands |
| Non-covalent, hormone-induced homodimerization | because the annotated disulfides are intrachain rather than inter-chain, the ligand-induced dimer dissociates under reducing SDS-PAGE, so no covalent dimer band is expected |
| Intrachain disulfide bonds (Cys36-Cys46, Cys75-Cys86) | stabilize extracellular domain folding; incomplete reduction can subtly alter migration without producing a dimer-sized band |
| Situation | Likely cause | Next action |
|---|---|---|
| Band higher than expected | extensive N-glycosylation at the three extracellular asparagines raises the apparent mass above the 69.5 kDa predicted backbone | treat lysate with PNGase F and confirm the deglycosylated product shifts down toward ~69.5 kDa |
| Broad smear instead of sharp band | heterogeneous glycan occupancy and processing across the three N-glycosylation sites | run a longer gradient gel, extend transfer time for the higher-MW glycoprotein, or deglycosylate to sharpen the band |
| Multiple bands | the 9 annotated PRLR splice isoforms, including distinct membrane-bound and soluble forms | compare observed masses to isoform lengths or use isoform-selective antibodies to assign each band |
| No band in lysate | a soluble/secreted PRLR isoform released into the medium rather than retained in the cell pellet | analyze concentrated conditioned medium alongside whole-cell lysate |
| Weak or no signal | low endogenous PRLR expression in cell types with limited receptor density | enrich the membrane fraction, load more total protein, or use a tissue/cell line with known high PRLR expression |
| Fragments below expected size | proteolytic degradation of the glycosylated extracellular domain during lysis | prepare lysates fresh with protease inhibitors and compare against a mammalian-expressed positive control |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|
| Tissue | Cell type | Level | Evidence | Source |
|---|
Deeper troubleshooting and optimisation questions for PRLR, answered from its protein features.
BosterBio's PRLR antibodies are among the best-performing WB antibodies on the market — well cited, thoroughly validated, and orthogonally cross-validated against negative tissues and complementary methods.
Boster's anti-PRLR antibodies (PB9782, PA2087) are top-performing, extensively cited reagents validated by Western blot and orthogonally cross-checked against negative-tissue controls and complementary detection methods, ensuring specific, reproducible PRLR detection you can trust for critical experiments.
Which to pick: Both PB9782 and PA2087 include genuine Western blot validation images on PRLR-expressing samples, making either a reliable choice; since both are equally supported, selection can come down to lot availability or personal preference.